Discover seven lung cancer companies advancing promising candidates through the clinic, from viral immunotherapies to ...

NeoGenomics announced the commercial launch of c-MET CDx for NSCLC, its c-MET companion diagnostic immunohistochemistry (IHC) ...

Shares of Instil Bio climbed after the company shared progress on a trial in China for its non-small cell lung cancer treatment in combination with chemotherapy and said it is preparing to start U.S.

The FDA has granted fast-track approval to the drug telisotuzumab vedotin (sold as Emrelis) as a first-of-its-kind treatment ...

Investigators are using MET immunohistochemistry testing and FDA-approved profiling tools to personalize care and address unmet needs in NSCLC treatment.

AbbVie's Emrelis is the first non-small cell lung cancer therapy approved for patients with high c-Met expression levels who ...

Novel combination achieves 60.8% response rate and 90.2% disease control rate in first-line non-small cell lung cancer (1L ...

Higher-than-usual doses of radiation in the treatment of inoperable lung cancer can be safely combined with immunotherapy ...

Palliative radiation was allowed during treatment. Of all patients with mNSCLC enrolled ... CB, clinical benefit; ICI, immune checkpoint inhibitor; NSCLC, non–small cell lung cancer. From PROPHETIC, ...

For patients with EGFR-mutated NSCLC, treatment options in the frontline include osimertinib monotherapy, amivantamab with ...

The FDA granted accelerated approval to telisotuzumab vedotin (Emrelis) for the treatment of adults with previously treated, ...